Evidence map›Paper›PMID 32799883›Full record

ArticleJournal of translational medicine2020

Cancer patients and coronavirus disease 2019: evidence in context.

Maddalena Barba, Eriseld Krasniqi, Gennaro Ciliberto, Patrizia Vici

Open access · goldAbstract readLetterComment
In one paragraph

Article in Journal of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Cancer Patients during COVID-19 Pandemic: A Mini-Review.Healthcare (Basel, Switzerland) · 2023
    Review
  2. Review
  3. Review
  4. Predictions of cancer mortality in Europe in 2021: room for hope in the shadow of COVID-19?Annals of oncology : official journal of the European Society for Medical Oncology · 2021
    Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Maddalena BarbaDivision of Medical Oncology 2, IRCCS IFO-Regina Elena National Cancer Institute, 00144, Rome, Italy. maddalena.barba@gmail.com.ORCID 0000-0001-9050-2917
Eriseld KrasniqiDivision of Medical Oncology 2, IRCCS IFO-Regina Elena National Cancer Institute, 00144, Rome, Italy.
Gennaro CilibertoScientific Direction, IRCCS IFO-Regina Elena National Cancer Institute, 00144, Rome, Italy.
Patrizia ViciDivision of Medical Oncology 2, IRCCS IFO-Regina Elena National Cancer Institute, 00144, Rome, Italy.
Istituti Fisioterapici Ospitalieri · ITNational Cancer Institute · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the rapidly evolving coronavirus disease 2019 (COVID-19) outbreak, inherent literature has been increasing at an impressive rate. Such a dynamic scenario imposes the necessity to define a new framework for cancer care. The first emerging evidence has transmitted contrasting messages with regards to cancer care management. Some authors have hypothesized an increased infection risk for cancer patients, with a more severe disease, requiring a reorganization of health care system that could disrupt an established high quality cancer care routine in many developed countries. Other authors have attempted to interpret data related to cancer patients by better defining their "active status". We herein present our point of view in the light of current evidence and based on the experience matured at our cancer institute in managing cancer patients during the COVID-19 pandemic. Our core idea is that "active cancer" may be considered a proxy of more recent exposure to diagnostic or therapeutic procedures, and the frequency of access to health care facilities can be predicted as a function of the severity of cancer symptoms. Hence, COVID-19 screening program and the adjustment of cancer care provision in a cancer institutions should be led by this risk model, while awaiting new evidence.

Indexed as

CoronavirusCoronavirus InfectionsPandemicsPneumonia, ViralBetacoronavirusChinaCOVID-19HumansSARS-CoV-2Cancer careCancer patientsCOVID-19 pandemicHealth care reorganization

Identifiers

PMID32799883
PMCPMC7429080
OpenAlexW3048595957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.